RxDoctor Payments Data

Jose Rivera Irizarry, MD

Cardiovascular Disease · Arroyo, PRNPI 1851379606

Payments from drug & device makers

$2,565in general payments, 2019–2025

Across 115 payments — averaging $22.30 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson$624
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$584
  • Medtronic$514
  • Abbott$150
  • Actelion Pharmaceuticals US, Inc.$125
  • PBG Puerto Rico LLC$123
  • plus $445 from 6 others

What the payments were for

  • Food & beverage$2,565100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,565 in reported general payments places this provider in the 45th percentile of 267 cardiovascular disease providers in Puerto Rico.

See all cardiovascular disease providers in Puerto Rico

Medicare billing

Part B allowed, 2024
$30,016
Medicare patients
97
Services billed
299

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XareltoRivaroxaban654$637,402
EliquisApixaban176$191,192
BrilintaTicagrelor75$63,029
JanuviaSitagliptin Phosphate63$60,709
SynthroidLevothyroxine Sodium507$56,513
JardianceEmpagliflozin48$53,062
Omega-3 Acid Ethyl Esters328$50,831
TradjentaLinagliptin49$50,564
FarxigaDapagliflozin Propanediol24$32,043
Candesartan Cilexetil155$21,850
Metoprolol Succinate1,075$21,713
JentaduetoLinagliptin/Metformin Hcl19$16,973
Pentoxifylline158$15,680
JanumetSitagliptin Phos/Metformin Hcl22$14,709
Rosuvastatin Calcium864$14,473

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonXarelto$624$637,402654 claims
Boehringer IngelheimJardiance, Tradjenta, Jentadueto$112$120,600116 claims
AstraZenecaBrilinta, Farxiga, Crestor$105$108,266132 claims
MerckJanuvia, Janumet$74$75,41885 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 45th percentile of 267 cardiovascular disease providers in Puerto Rico.

Other cardiovascular disease in Arroyo

See the full list for Puerto Rico

Where these figures come from

Is this you, or does something look wrong? →